country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-116528

Copy Link Print Information

GCA-186

GCA-186 is a potent anti-HIV-1 agent. GCA-186 is highly active against both wild type and mutated HIV-1 strains with EC₅₀s of 1, 180, 1, and 40 nM for III_B, III_B-R(Y181C), NL4-3 and NL4-3_K103N of HIV-1 strains, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 149950-61-8
Formel: C₁₉H₂₆N₂O₃
Molecular Weight:330.42

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (271 KB)

GCA-186 Chemical Structure

CAS. Nr.: 149950-61-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle HIV Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CEM-SS	IC₅₀	0.6 nM Compound: 28	Tested for inhibitory concentration on HIV-I Lai wild type in CEM-SS cell line Tested for inhibitory concentration on HIV-I Lai wild type in CEM-SS cell line	[PMID: 11052800]
CEM-SS	CC₅₀	43 μM Compound: 28	Tested for cytotoxic concentration on HIV-I Lai wild type in CEM-SS cell line Tested for cytotoxic concentration on HIV-I Lai wild type in CEM-SS cell line	[PMID: 11052800]
HeLa	CC₅₀	52.5 μM Compound: GCA-186	Compound was tested for its cytotoxicity depending on the viability of mock-infected cells Compound was tested for its cytotoxicity depending on the viability of mock-infected cells	[PMID: 10579814]
HeLa	EC₅₀	0.001 μM Compound: GCA-186	Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like IIIB Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like IIIB	[PMID: 10579814]
HeLa	EC₅₀	0.001 μM Compound: GCA-186	Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like NL4-3 Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like NL4-3	[PMID: 10579814]
HeLa	EC₅₀	0.04 μM Compound: GCA-186	Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like NL4-3K103N Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like NL4-3K103N	[PMID: 10579814]
HeLa	EC₅₀	0.18 μM Compound: GCA-186	Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like IIIB-R(Y181C) Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like IIIB-R(Y181C)	[PMID: 10579814]
MT4	IC₅₀	0.001 μM Compound: GCA-186	Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	IC₅₀	0.04 μM Compound: GCA-186	Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	IC₅₀	0.18 μM Compound: GCA-186	Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	CC₅₀	43 μM Compound: 34	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 7636846]
MT4	EC₅₀	0.0006 μM Compound: 34	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus.	[PMID: 7636846]
MT4	EC₅₀	0.6 nM Compound: 34	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus.	[PMID: 7636846]

In Vitro

GCA-186 shows antiviral activity (EC₅₀=0.6 nM) and cytotoxicity against HIV-1 in MT-4 cells (CC₅₀=43 μM)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 149950-61-8
Molecular Weight 330.42
Formel C₁₉H₂₆N₂O₃
SMILES

O=C1NC(C(C(C)C)=C(N1COCC)CC2=CC(C)=CC(C)=C2)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. El-Brollosy NR, et al. Synthesis and antiviral evaluation of 6-(trifluoromethylbenzyl) and 6-(fluorobenzyl) analogues of HIV drugs emivirine and GCA-186. Arch Pharm (Weinheim). 2008;341(1):9-19. [Content Brief]

[2]. Hopkins AL, et al. Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants. J Med Chem. 1999;42(22):4500-4505. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- In Vitro
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

GCA-186

Alle HIV Isoform-spezifische Produkte anzeigen